Zusammenfassung
Die Hämostase ist ein komplexes, fein reguliertes Zusammenspiel von Vorgängen, die einerseits die Fließfähigkeit des Blutes im Gefäßsystem aufrechterhalten, andererseits bei einer Verletzung einen sofortigen Gefäßverschluss ermöglichen und Reparaturvorgänge zur Wiederherstellung der Gefäßstruktur einleiten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Zu 5.1.1–5.1.3, 5.1.5, 5.1.6
Alban S (2010) Heparine und andere Glykoantikoagulanzien. In: Pötzsch B, Madlener K (Hrsg) Hämostaseologie, 2. Aufl. Springer, Berlin, Heidelberg, New York
Anderson JL et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563–2570
Bauersachs RM (2008) New anticoagulants. Hamostaseologie 28:21–26
Bauersachs R, Alban S (2007) Perioperative bridging with fondaparinux in a woman with antithrombin deficiency. Thromb Haemost 97:498–499
Bauersachs RM, Lindhoff-Last E, Ehrly AM et al (1999) Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb Haemost 81:323–324
Elalamy I, Lecrubier C, Potevin F et al (1995) Absence of in vitro crossreaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 74:1384–1385
Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM (2005) Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127:2049–2056
GlaxoSmithKline GmbH, Co KG (2008) Fachinformation Arixtra®
Harenberg J, Huhle G, Hoffmann U (1998) Pharmakologie der Heparine und Heparinoide. In: Müller -BerghausG, Pötzsch B (Hrsg) Hämostaseologie. Springer, Berlin, Heidelberg, New York
Klein TE et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753–764
Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673–684
Meda (2011) Fachinformation Marcumar®
Oldenburg J, Bevans CG, Muller CR, Watzka M (2006) Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 8:347–353
Palareti G (2011) Bleeding with anticoagulant treatments. Hamostaseologie 31:237–242
van Leeuwen Y, Rosendaal FR, van der Meer FJ (2008) The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon. Thromb Res 123:225–230
Zu 5.1.4
Blech S, Ebner T, Ludwig-Schwellinger E et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399
Frost C, Yu Z, Moore K et al. (2007) Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 5: P-M–664
He K, He B, Grace JE et al (2006) Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor. ASH Annual Meeting Abstracts 108:91–0
Kubitza D, Becka M, Voith B et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421
Kubitza D, Becka M, Zuehlsdorf M et al (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47:218–226
Lang D, Freudenberger C, Weinz C (2009) In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 37:1046–1055
Perzborn E, Strassburger J, Wilmen A et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 3:514–521
Pinto DJ, Orwat MJ, Koch S et al (2007) Discovery of 1-(4-methoxyphenyl)- 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H -pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339–5356
Raghavan N, Frost CE, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81
Roehrig S, Straub A, Pohlmann J et al (2005) Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin- 4-yl)phenyl]-1,3-oxazolidin- 5-yl}methyl)thiophene- 2- carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005 48:5900–5908
Stangier J, Eriksson BI, Dahl OE et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45:555–563
Stangier J, Stahle H, Rathgen K et al (2008a) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48:1411–1419
Stangier J, Stahle H, Rathgen K et al (2008b) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47–59
Ufer M (2010) Comparative efficiacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 103:572–585
Weinz C, Radtke M, Schmeer K et al (2004) In vitro metabolism of BAY 59-7939 - an oral, direct factor Xa inhibitor [abstract no. 195]. Drug Metab Rev 36(Suppl 1):9–8
Weinz C, Schwarz T, Kubitza D et al (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37:1056–1064
Wienen W, Stassen JM, Priepke H et al (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155–162
Wong PC, Crain EJ, Xin B et al (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6:820–829
Zhang D, He K, Raghavan N et al (2009) Comparative Metabolism of C-14 Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans. Drug Metab Dispos 37:1738–1748
Zu 5.2
Anderson DR, Dunbar MJ, Bohm ER et al (2013) Aspirin versus low- molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 158:800–806
Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 308:235–246
Becattini C, Agnelli G, Schenone A et al (2012) Aspirin for preventing the recurrence of venous thromboembolism. New Engl J Med 366:1959–1967
Beksac B, Gonzalez DValleeA, Anderson J, Sharrock NE, Sculco TP, Salvcato EA (2007) Symptomatic thrombembolism after on-stage bilateral THA with a multimodal prophylaxis protocol. Clin Orthop Relat Res 463:114–119
Berend KR, Lombardi AV Jr (2006) Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin. Am J Orthop 35:24–29
Bird JE, Wang X, Smith PL, Barbera F, Huang C, Schumacher WA (2012) A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis. J Thromb Thrombolysis 34:199–207
Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD (2010) Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 7:1053–1060
Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormers J, Hansen JB (2009) Mean platelet volume is a risk factor for venous thrombembolism: The Tromso study. J Thromb Haemostasis: 8: 157–162
Brighton TA, Eikelboom JW, Mann K et al (2012) Low-dose Aspirin for preventing recurrent venous thromboembolism. New Engl J Med 367:1979–1987
Brown GA (2009) Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. J Arthroplasty 6(Suppl):77–83
Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW (2008) Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. J Arthroplasty 23(Suppl 1):20–24
Canadian Agency for Drugs and Technologies in Health. Acetylsalicylic acid for venous thromboembolism prophylaxis: clinical evidence, benefits and harms [Internet]. Ottawa: the Agency; 2011 Jun 23. (Rapid response report: summary of abstracts). http://cadth.ca/media/pdf/htis/june-2011/RB0383_ASA_for_VTE_Final.pdf
Cesarone MR, Belcaro G, Nicolaides AN et al (2002) Venous thrombosis from air travel: the LONFLIT3 study-prevention with aspirin vs. low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology 53:1–6
Cooley BC, Herrera AJ (2013) Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis. Blood Coagul Fibrinolysis 2013, epub ahead of print
Intermountain Joint Replacement Center Writing Committee (2012) A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthoplasty 27: 1-9e
Ji H-M, Lee Y-K, Ha Y-C, Kim H-C, Koo K-H (2011) Little impact of antiplatelet agents on venous thrombembolism after hip fracture surgery. J Korean Med Sci 26:1625–1629
Leon C, Alex M, Klocke A, Morgenstern E, Moosbauer C, Eckly A, Spannagl M, Gachet C, Engelmann B (2004) Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 103:594–600
Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC (2011) Relationship between venous and arterial thrombosis: A review of the literature from a causal perspective. Sem Thromb Hemostas 37:885–896
Loke YK, Derry S (2002) Air travel and venous thrombosis: how much help might aspirin be? Med Gen Med 4:4
Lopez JA, Chen J (2009) Pathophysiology of venous thrombosis. Thromb Res 123(Suppl 4):S30–S34
Lotke PA, Lonner JH (2006) The benefit of aspirin chemoprophylaxis for thrombembolism after total knee arthroplasty. Clin Orthop Rel Res 452:175–180
Lyman GH, Khorana AA, Kuderer NM et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 31:2189–2204
Marsland D, Mears SC, Kates SL (2010) Venous thromboembolic prophylaxis for hip fractures. Osteoporos Int 21(Suppl 4):S593–S604
Pulmonary embolism prevention (PEP) trial collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary embolism prevention (PEP) trial. The Lancet 355:1295–1302
Qaseem A, Chou R et al (2011) Venous thrombembolism prophylaxis in hospitalized patients: A clinical practice guideline from the American College of Physicians. Ann Int Med 155:625–632
Rosendaal FR (1999) Venous thrombosis: a multicausal disease. The Lancet 353:1167–1173
Schann TA, Lstler L, Engoren MC, Habib RH (2010) Incidence and predictors of postoperative deep vein thrombosis in cardiac surgery in the era of aggressive thromboprophylaxis. Ann Thorac Surg 90:760–766
Schellong S (2013) Aspirin for long-term maintainance of venous thromboembolism. Vasa 42:83–85
Schrör K (2011) Acetylsalicylsäure. Dr.Schrör-Verlag, Frechen, S 239–244
Sevitt S (1974) The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 27:517–528
Sharrock NE, Della Valle AG et al (2008) Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 466:714–721
Stewart DW, Freshour JE (2013) Aspirin for the prophylaxis of venolus thromboembolic evebnts in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother 47:63–74
Turpie AGG, Esmon C (2011) Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation. Thromb Haemost 105:586–596
Warkentin TE (2012) Aspirin for dual prevention of venous and arterial thrombosis. New Engl J Med 367:2039–2041
Watson HG, Chee YL (2008) Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Rev 22:107–116
Westrich GH, Sculco TP (1996) Prophylaxis against deep venous thrombosis after total knee arthroplasty. J Bone Joint Surg 78A:826–834
Zu 5.3
Althaus K, Hron G, Strobel U, Abbate R, Rogolino A, Davidson S, Greinacher A, Bakchoul T (2013) Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res 31:e85–e90
Linkins LA, Dans AL, Moores LK, Bona R, Davodson BL, Schulman S, Crowther M (2012) Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest 141 (2 Suppl): e495S–530S
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765
Kelton JG, Arnold DM, Bates SM (2013) Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia. New Engl J Med 368:737–744
Thiele T, Althaus K, Greinacher A (2010) Heparin-induced thrombozytopenia. Internist (Berl) 51:1127–1132
Warkentin TE (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555
Zu 5.4
Arzneimittelkommission der Deutschen Ärzteschaft (2011) Risiko von venösen Thromboembolien bei Einnahme von Drospirenon-haltigen kombinierten oralen Kontrazeptiva. Ärzteblatt 108:A244–2
Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R (2005) Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 116:1–13
Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN (2003) Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The Breast Cancer Prevention Trial. Br J Haematol 120:109–116
DeLoughery TG (2011) Estrogen and thrombosis: controversies and common sense. Rev Endocr Metab Disord 12:77–84
Deutsche Gesellschaft für Hämato-Onkologie (2011) Leitlinie Multiples Myelom. http://www.dgho-onkopedia.de/onkopedia/leitlinien/multiples-myelom
Dinger JC, Heinemann LA, Kuhl-Habich D (2007) The safety of a drospirenone- containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75:344–354
Dunn N (2011) The risk of deep venous thrombosis with oral contraceptives containing drospirenone. Br Med J 342:d251–9
Gomes MP, Deitcher SR (2004) Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164:1965–1976
Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132:689–696
Gräser T (2001) Sexualsteroide und Hämostase. Hämostaseologie 21:30–34
Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:555–568
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin- Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. The Lancet 365:60–62
Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzen F, Lyman GH, Rohr UP (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29:1757–1764
Jick SS, Hernandez RK (2011) Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. Br Med J 342:d215–1
Kemmeren JM, Algra A, Grobbee DE (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 323:131–134
Kristinsson SY (2010) Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010: 437–444
Larocca A, Cavallo F, Bringhen S et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119:933–939
Lechner D, Weltermann A (2009) Pathophysiology of chemotherapyassociated thrombosis. Hämostaseologie 29:112–120
Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b289–0
Lopez JA, Chen J (2009) Pathophysiology of venous thrombosis. Thromb Res 123(Suppl 4):S30–S34
Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285
Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancerassociated thrombosis. Br J Cancer 102(Suppl 1):S2–S9
Palumbo A, Cavo M, Bringhen S et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29:986–993
Parkin L, Sharples K, Hernandez RK, Jick SS (2011) Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: Nested case-control study based on UK General Practice Research Database Br Med J 342: d2139
Patrassi GM, Sartori MT, Rigotti P, Di-Landro D, Theodoridis P, Fioretti M, Capalbo M, Saggiorato G, Boeri G, Girolami A (1995) Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. Transplantation 59:1416–1420
Rosendaal FR (1999) Venous thrombosis: a multicausal disease. The Lancet 353:1167–1173
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
van Hylckama V, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR (2009) The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339:b292–1
van Vliet HA, Tchaikovski SN, Rosendaal FR, Rosing J, Helmerhorst FM (2009) The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). Thromb Haemost 101:691–695
Winkler UH (2000) Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 62:11S–20S
Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I (2006) Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10:1–110
Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M (2011) Multiple myeloma, venous thromboembolism, and treatmentrelated risk of thrombosis. Semin Thromb Hemost 37:209–219
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bauersachs, R., Kröger, M., Schrör, K., Hohlfeld, T., Spannagl, M., Hart, C. (2014). Pharmakologie. In: Nüllen, H., Noppeney, T., Diehm, C. (eds) VTE - Venöse Thromboembolien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21496-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-21496-7_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-21495-0
Online ISBN: 978-3-642-21496-7
eBook Packages: Medicine (German Language)